X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (19324) 19324
Magazine Article (182) 182
Book / eBook (24) 24
Newsletter (15) 15
Book Review (12) 12
Dissertation (6) 6
Book Chapter (5) 5
Conference Proceeding (5) 5
Publication (5) 5
Government Document (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (18415) 18415
female (9712) 9712
male (8769) 8769
antidepressive agents - therapeutic use (8629) 8629
antidepressive agents - adverse effects (7550) 7550
psychiatry (7099) 7099
adult (6872) 6872
middle aged (5887) 5887
antidepressants (5068) 5068
aged (4226) 4226
pharmacology & pharmacy (4087) 4087
depressive disorder - drug therapy (4017) 4017
depression (3897) 3897
treatment outcome (3479) 3479
depression - drug therapy (2713) 2713
depressive disorder, major - drug therapy (2613) 2613
adolescent (2387) 2387
double-blind (2336) 2336
clinical neurology (2295) 2295
neurosciences (2271) 2271
antidepressive agents, second-generation - adverse effects (2234) 2234
antidepressive agents, tricyclic - adverse effects (2157) 2157
serotonin uptake inhibitors - adverse effects (1995) 1995
risk factors (1958) 1958
antidepressive agents, second-generation - therapeutic use (1926) 1926
animals (1921) 1921
major depression (1873) 1873
antidepressive agents, tricyclic - therapeutic use (1862) 1862
antidepressive agents - administration & dosage (1847) 1847
serotonin uptake inhibitors - therapeutic use (1847) 1847
depression, mental (1726) 1726
double-blind method (1717) 1717
drug therapy, combination (1644) 1644
fluoxetine (1573) 1573
psychiatric status rating scales (1535) 1535
depressive disorder - psychology (1516) 1516
drug therapy (1492) 1492
antidepressive agents - pharmacology (1475) 1475
major depressive disorder (1428) 1428
medicine, general & internal (1414) 1414
dose-response relationship, drug (1397) 1397
efficacy (1344) 1344
serotonin reuptake inhibitors (1323) 1323
drug interactions (1319) 1319
mental depression (1229) 1229
antidepressant (1225) 1225
antipsychotic agents - therapeutic use (1165) 1165
antipsychotic agents - adverse effects (1154) 1154
care and treatment (1150) 1150
child (1143) 1143
risk (1125) 1125
young adult (1122) 1122
aged, 80 and over (1076) 1076
bipolar disorder - drug therapy (1047) 1047
time factors (1042) 1042
analysis (1028) 1028
pregnancy (1027) 1027
comorbidity (1021) 1021
research (1021) 1021
randomized controlled trials as topic (996) 996
drugs (992) 992
prevalence (962) 962
serotonin (957) 957
depressive disorder, major - psychology (899) 899
placebo (880) 880
medicine & public health (879) 879
paroxetine (853) 853
psychology, clinical (849) 849
anxiety (843) 843
clinical trials as topic (829) 829
psychotherapy (823) 823
health aspects (810) 810
drug administration schedule (767) 767
retrospective studies (754) 754
depressive disorder - diagnosis (745) 745
placebo-controlled trial (745) 745
bipolar disorder (735) 735
follow-up studies (730) 730
venlafaxine hydrochloride (728) 728
internal medicine (723) 723
metaanalysis (719) 719
rats (705) 705
depressive disorder, major - diagnosis (699) 699
sertraline (696) 696
clinical trials (686) 686
fluoxetine - adverse effects (685) 685
psychology (682) 682
pharmacotherapy (681) 681
serotonin uptake inhibitors (678) 678
antidepressive agents (676) 676
fluoxetine - therapeutic use (669) 669
antidepressants, tricyclic (666) 666
prospective studies (664) 664
combined modality therapy (662) 662
symptoms (659) 659
venlafaxine (658) 658
severity of illness index (652) 652
antidepressive agents, second-generation - administration & dosage (651) 651
disorder (651) 651
dosage and administration (634) 634
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (11) 11
Collection Dvlpm't (Acquisitions) - Vendor file (4) 4
UofT at Scarborough - Stacks (3) 3
Gerstein Science - Periodical Stacks (2) 2
University College (Laidlaw) - Stacks (2) 2
UofT at Mississauga - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Online Resources - Online (1) 1
Providence Healthcare - Stacks (1) 1
Robarts - Stacks (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Patient Education (1) 1
Toronto East General Hospital - Chaplain Dept. (1) 1
UofT Schools - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (17684) 17684
German (596) 596
French (559) 559
Spanish (161) 161
Japanese (139) 139
Russian (100) 100
Norwegian (99) 99
Danish (84) 84
Dutch (71) 71
Swedish (69) 69
Polish (65) 65
Italian (64) 64
Portuguese (55) 55
Hungarian (38) 38
Finnish (20) 20
Czech (17) 17
Chinese (15) 15
Turkish (15) 15
Romanian (6) 6
Hebrew (5) 5
Icelandic (3) 3
Korean (3) 3
Lithuanian (2) 2
Slovak (2) 2
Bosnian (1) 1
Croatian (1) 1
Serbian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of hepatology, ISSN 0168-8278, 2012, Volume 58, Issue 4, pp. 792 - 800
Summary Hepatitis C virus (HCV) infected patients often take multiple co-medications to treat adverse events related to HCV therapy, or to manage other co-morbidities. Drug... 
Gastroenterology and Hepatology | Boceprevir | Hepatitis C virus infection | Telaprevir | Pharmacokinetics | Drug interactions | CHRONIC HEPATITIS-C | GASTROENTEROLOGY & HEPATOLOGY | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Hepatitis C, Chronic - metabolism | Antiviral Agents - pharmacokinetics | Hypnotics and Sedatives - adverse effects | Humans | Hypnotics and Sedatives - administration & dosage | Drug Interactions | Hypoglycemic Agents - administration & dosage | Drug Therapy, Combination | Immunosuppressive Agents - administration & dosage | Cardiovascular Agents - administration & dosage | Anti-Infective Agents - adverse effects | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Opiate Substitution Treatment - adverse effects | Buprenorphine - administration & dosage | Anti-Infective Agents - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Antiviral Agents - adverse effects | Buprenorphine - adverse effects | Antidepressive Agents - administration & dosage | Immunosuppressive Agents - adverse effects | Methadone - administration & dosage | Methadone - adverse effects | Antidepressive Agents - adverse effects | Cardiovascular Agents - adverse effects | Hypoglycemic Agents - adverse effects | Hepatitis C virus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 388, Issue 10047, pp. 881 - 890
Summary Background Major depressive disorder is one of the most common mental disorders in children and adolescents. However, whether to use pharmacological... 
Internal Medicine | TRIALS | MEDICINE, GENERAL & INTERNAL | ACCEPTABILITY | MENTAL-HEALTH-CARE | TRENDS | GUIDELINES | Mianserin - adverse effects | Triazoles - administration & dosage | Triazoles - adverse effects | Humans | Citalopram - adverse effects | Sertraline - adverse effects | Venlafaxine Hydrochloride - adverse effects | Imipramine - administration & dosage | Paroxetine - adverse effects | Mianserin - analogs & derivatives | Paroxetine - administration & dosage | Desipramine - adverse effects | Nortriptyline - administration & dosage | Nortriptyline - adverse effects | Mianserin - administration & dosage | Child | Fluoxetine - adverse effects | Depressive Disorder, Major - drug therapy | Clomipramine - administration & dosage | Duloxetine Hydrochloride - adverse effects | Double-Blind Method | Drug Administration Schedule | Treatment Outcome | Clomipramine - adverse effects | Evidence-Based Medicine | Desipramine - administration & dosage | Randomized Controlled Trials as Topic | Venlafaxine Hydrochloride - administration & dosage | Citalopram - administration & dosage | Confounding Factors (Epidemiology) | Sertraline - administration & dosage | Adolescent | Amitriptyline - adverse effects | Bayes Theorem | Fluoxetine - administration & dosage | Duloxetine Hydrochloride - administration & dosage | Antidepressive Agents - administration & dosage | Antidepressive Agents - adverse effects | Research Design | Amitriptyline - administration & dosage | Imipramine - adverse effects | Psychological aspects | Medical colleges | Neurosciences | Drugs and youth | Rankings | Comparative analysis | Child psychopathology | Major depressive disorder | Antidepressants, Tricyclic | Pediatric pharmacology | Mental illness | Studies | Teenagers | Mental depression | Antidepressants | Meta-analysis | Children & youth
Journal Article
Drug Safety, ISSN 0114-5916, 2/2011, Volume 34, Issue 2, pp. 125 - 156
Background: Many individuals in the community are prescribed psychoactive drugs with sedative effects... 
Medicine & Public Health | Drug Safety and Pharmacovigilance | Pharmacology/Toxicology | Flurazepam, adverse reactions | Benzodiazepines, adverse reactions | Zopiclone, adverse reactions | Driving | Temazepam, adverse reactions | Nitrazepam, adverse reactions | Tricyclic-antidepressants, adverse reactions | Flunitrazepam, adverse reactions serious | Meta-analysis | Zolpidem, adverse reactions | Serotonin-uptake-inhibitors, adverse reactions | Antidepressants, adverse reactions | Triazolam, adverse reactions | Opioid-analgesics, adverse reactions | Lorazepam, adverse reactions | COGNITIVE FUNCTIONS | MOTOR-VEHICLE ACCIDENTS | DAYTIME SLEEPINESS | ROAD-TRAFFIC ACCIDENTS | NEUROPATHIC PAIN PATIENTS | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | PSYCHOMOTOR PERFORMANCE | CHRONICALLY ADMINISTERED BUSPIRONE | ON-THE-ROAD | PHARMACOLOGY & PHARMACY | TOXICOLOGY | HEALTHY-VOLUNTEERS | 1 MG | Epidemiologic Studies | Humans | Risk Factors | Analgesics, Opioid - therapeutic use | Male | Antidepressive Agents - therapeutic use | Analgesics, Opioid - adverse effects | Risk-Taking | Accidents, Traffic - statistics & numerical data | Female | Benzodiazepines - adverse effects | Antidepressive Agents - adverse effects | Automobile Driving | Benzodiazepines - therapeutic use | Research Design | Prevention | Complications and side effects | Opioids | Dosage and administration | Traffic accidents | Benzodiazepines | Risk factors | Antidepressants, Tricyclic
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2017, Volume 152, Issue 5, pp. 1078 - 1089
... (OR, 2.0; 95% CI, 1.6-2.5; P = 9.7 x 10.sup.-9). The association with A*33:01 was mediated by large effects for terbinafine-, fenofibrate-, and ticlopidine-related DILI... 
Gastroenterology and Hepatology | Side Effect | Medication | Liver Damage | Anti-Fungal Agent | POPULATION | SUSCEPTIBILITY | RISK | TERBINAFINE | TICLOPIDINE | HEPATITIS | CLASS-I | HEPATOTOXICITY | GASTROENTEROLOGY & HEPATOLOGY | T-CELLS | ANTIGEN | Antifungal Agents - adverse effects | Naphthalenes - adverse effects | Humans | Middle Aged | Male | Sertraline - adverse effects | Fenofibrate - adverse effects | Chromosomes, Human, Pair 2 - genetics | Ticlopidine - adverse effects | Female | Odds Ratio | Chemical and Drug Induced Liver Injury - etiology | Platelet Aggregation Inhibitors - adverse effects | Hypolipidemic Agents - adverse effects | European Continental Ancestry Group - genetics | Genetic Predisposition to Disease | Genome-Wide Association Study | Genes, MHC Class I - genetics | Chemical and Drug Induced Liver Injury - genetics | Terbinafine | Phenotype | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Alleles | HLA-A Antigens - genetics | Polymorphism, Single Nucleotide | Antidepressive Agents - adverse effects | Drugs | Medical research | Liver diseases | Liver | Genes | Genomics | Risk factors | Genetic polymorphisms | Analysis | Gastrointestinal diseases | Medicine, Experimental | Genetic research | Trade and professional associations | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology | Hépatology and Gastroenterology | side effect | medication | anti-fungal agent | liver damage
Journal Article
JAMA psychiatry (Chicago, Ill.), ISSN 2168-622X, 09/2014, Volume 71, Issue 9, pp. 1006 - 1014
Journal Article
JAMA psychiatry (Chicago, Ill.), ISSN 2168-622X, 05/2015, Volume 72, Issue 5, pp. 438 - 445
IMPORTANCE: Antipsychotic medications are associated with increased mortality in older adults with dementia, yet their absolute effect on risk relative to no treatment or an alternative psychotropic is unclear. OBJECTIVE... 
MORTALITY | MEDICATIONS | METAANALYSIS | EFFICACY | PSYCHIATRY | ALZHEIMERS-DISEASE | NEUROPSYCHIATRIC SYMPTOMS | OLDER-ADULTS | DRUGS | PLACEBO-CONTROLLED TRIALS | ATYPICAL ANTIPSYCHOTICS | United States - epidemiology | Antipsychotic Agents - adverse effects | Humans | Middle Aged | Male | Risk | Case-Control Studies | Dose-Response Relationship, Drug | Psychotropic Drugs - adverse effects | Dibenzothiazepines - adverse effects | Risperidone - adverse effects | Female | Registries | Retrospective Studies | Dementia - drug therapy | Quetiapine Fumarate | Veterans - psychology | Psychotropic Drugs - administration & dosage | Haloperidol - adverse effects | Dementia - mortality | Antipsychotic Agents - administration & dosage | Aged | Benzodiazepines - adverse effects | Veterans - statistics & numerical data | Antidepressive Agents - adverse effects | Dosage and administration | Antipsychotic drugs | Mortality | Analysis | Risk factors | Dementia | Veterans | Comorbidity | Americans | Survivors | Outpatient Treatment | Longitudinal Study | Psychiatric Disorders | Epidemiology | Benzodiazepines | Conventional Antipsychotics | Anticonvulsants | Cognitive Disorders | Etiology | Psychopharmacology | Opioids | Aging | Antidepressant Drugs | Atypical Antipsychotics | PTSD (ICD-9) | Negative Therapeutic Reaction
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 05/2018, Volume 2018, Issue 5, p. CD010753
Background Insomnia disorder is a subjective condition of unsatisfactory sleep (e.g. sleep onset, maintenance, early waking, impairment of daytime... 
Intervention | Condition | Paroxetine | Developmental, psychosocial & learning problems | Sleeping problems | Fluoxetine | Psychosocial problems | Antidepressive Agents | Trazodone | Sleep Initiation and Maintenance Disorders | Randomized Controlled Trials as Topic | Sleep disorders | Antidepressants | Antidepressive Agents, Tricyclic | All antidepressants | Population | Adult | Mianserin | Sleep initiation and maintenance disorders (primary insomnia) | Medicine General & Introductory Medical Sciences | Serotonin Uptake Inhibitors | DOXEPIN 1 MG | SLEEP DISTURBANCE | MEDICINE, GENERAL & INTERNAL | EFFICACY | DOUBLE-BLIND | OUTPATIENT TRIAL | QUALITY-OF-LIFE | MAJOR DEPRESSIVE DISORDER | ELDERLY-PATIENTS | PROLONGED-RELEASE MELATONIN | NIGHTLY TREATMENT | Mianserin - adverse effects | Trazodone - therapeutic use | Trazodone - adverse effects | Humans | Mianserin - therapeutic use | Serotonin Uptake Inhibitors - therapeutic use | Serotonin Uptake Inhibitors - adverse effects | Paroxetine - therapeutic use | Paroxetine - adverse effects | Antidepressive Agents - therapeutic use | Antidepressive Agents, Tricyclic - therapeutic use | Antidepressive Agents, Tricyclic - adverse effects | Antidepressive Agents - adverse effects | Fluoxetine - therapeutic use | Sleep Initiation and Maintenance Disorders - drug therapy | Fluoxetine - adverse effects
Journal Article
Cochrane library, ISSN 1465-1858, 2012, Volume 2012, Issue 11, p. CD004851
.... Objectives To determine the efficacy and adverse outcomes, including definitive suicidal behaviour and suicidal ideation, of newer generation antidepressants compared with placebo in the treatment... 
Intervention | Condition | Paroxetine | SSRIs | Fluoxetine | Mental health | Induction Chemotherapy | Depressive disorder, major | Depression | Depressive Disorder | Antidepressive Agents | Suicide | Depressive disorders & major depression | Sertraline | Citalopram | Randomized Controlled Trials as Topic | Antidepressants | Child health | Mood disorders | Population | Child & Adolescent | Exclusively child and/or adolescent poopulation | Medicine General & Introductory Medical Sciences | Serotonin Uptake Inhibitors | Fluoxetine [adverse effects; therapeutic use] | RISK-FACTORS | Humans | SUICIDAL IDEATION | Citalopram [administration & dosage; therapeutic use] | Depressive Disorder [drug therapy; psychology] | MAJOR DEPRESSION | Sertraline [administration & dosage; therapeutic use] | PHARMACOLOGICAL-TREATMENT | PULSE CLOMIPRAMINE | SEROTONIN REUPTAKE INHIBITORS | MEDICINE, GENERAL & INTERNAL | Suicide [psychology] | COGNITIVE-BEHAVIORAL THERAPY | Paroxetine [adverse effects; therapeutic use] | Adolescent | TERM FOLLOW-UP | DOUBLE-BLIND | Antidepressive Agents [adverse effects; therapeutic use] | Serotonin Uptake Inhibitors [adverse effects; therapeutic use] | PLACEBO-CONTROLLED TRIAL | Child | Serotonin Uptake Inhibitors - therapeutic use | Serotonin Uptake Inhibitors - adverse effects | Depressive Disorder - drug therapy | Paroxetine - therapeutic use | Paroxetine - adverse effects | Antidepressive Agents - therapeutic use | Citalopram - administration & dosage | Sertraline - administration & dosage | Sertraline - therapeutic use | Suicide - psychology | Citalopram - therapeutic use | Antidepressive Agents - adverse effects | Depressive Disorder - psychology | Fluoxetine - therapeutic use | Fluoxetine - adverse effects
Journal Article